These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

444 related articles for article (PubMed ID: 19194632)

  • 1. [Role of cytochrome P450 enzymes in the metabolism of antineoplastic drugs].
    Quiñones S L; Rosero P M; Roco A A; Moreno T I; Sasso A J; Varela F N; Cáceres L D; Saavedra S I
    Rev Med Chil; 2008 Oct; 136(10):1327-35. PubMed ID: 19194632
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of cytochrome P450 metabolism on drug response, interactions, and adverse effects.
    Lynch T; Price A
    Am Fam Physician; 2007 Aug; 76(3):391-6. PubMed ID: 17708140
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genotyping and phenotyping cytochrome P450: perspectives for cancer treatment.
    Mathijssen RH; van Schaik RH
    Eur J Cancer; 2006 Jan; 42(2):141-8. PubMed ID: 16325399
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Polymorphism of human cytochrome P450 enzymes and its clinical impact.
    Zhou SF; Liu JP; Chowbay B
    Drug Metab Rev; 2009; 41(2):89-295. PubMed ID: 19514967
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CYP450 pharmacogenetics for personalizing cancer therapy.
    van Schaik RH
    Drug Resist Updat; 2008 Jun; 11(3):77-98. PubMed ID: 18486526
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cytochrome P450 pharmacogenetics and cancer.
    Rodriguez-Antona C; Ingelman-Sundberg M
    Oncogene; 2006 Mar; 25(11):1679-91. PubMed ID: 16550168
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of cytochrome P450 in tumour development and progression and its potential in therapy.
    Murray GI
    J Pathol; 2000 Dec; 192(4):419-26. PubMed ID: 11113857
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The role of drug metabolizing enzymes in the effect and side-effect of the drugs].
    Vereczkey L; Jemnitz K; Monostory K; Veres Z; Kóbori L
    Orv Hetil; 2005 May; 146(19):947-52. PubMed ID: 15969306
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cancer pharmacogenomics: achievements in basic research.
    Nakajima M; Yokoi T
    Int J Clin Oncol; 2005 Feb; 10(1):14-9. PubMed ID: 15729595
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metabolism-based drug-drug interactions: what determines individual variability in cytochrome P450 induction?
    Tang C; Lin JH; Lu AY
    Drug Metab Dispos; 2005 May; 33(5):603-13. PubMed ID: 15673596
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Polymorphic cytochrome P450 enzymes and post-marketing drug dosage revisions: clinical relevance to dermatologic therapies.
    Saggar S; Maibach HI
    Cutan Ocul Toxicol; 2007; 26(3):171-80. PubMed ID: 17687682
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Current availability of genetic information of drug metabolizing enzymes, particularly on cytochrome P450(CYP)].
    Yamazoe Y; Nagata K
    Nihon Rinsho; 2001 Aug; 59(8):1614-23. PubMed ID: 11519169
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drug-induced changes in P450 enzyme expression at the gene expression level: a new dimension to the analysis of drug-drug interactions.
    Lee MD; Ayanoglu E; Gong L
    Xenobiotica; 2006; 36(10-11):1013-80. PubMed ID: 17118918
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Study of the molecular mechanism of human cytochrome P450 and genetic polymorphism of drug oxidative metabolizing enzyme].
    Zhao L; Lou YQ
    Sheng Li Ke Xue Jin Zhan; 1997 Jan; 28(1):35-40. PubMed ID: 10921075
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Liver enzyme induction and inhibition: implications for anaesthesia.
    Sweeney BP; Bromilow J
    Anaesthesia; 2006 Feb; 61(2):159-77. PubMed ID: 16430569
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Validation of in vitro cell models used in drug metabolism and transport studies; genotyping of cytochrome P450, phase II enzymes and drug transporter polymorphisms in the human hepatoma (HepG2), ovarian carcinoma (IGROV-1) and colon carcinoma (CaCo-2, LS180) cell lines.
    Brandon EF; Bosch TM; Deenen MJ; Levink R; van der Wal E; van Meerveld JB; Bijl M; Beijnen JH; Schellens JH; Meijerman I
    Toxicol Appl Pharmacol; 2006 Feb; 211(1):1-10. PubMed ID: 15975613
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genetic factors in drug metabolism.
    Belle DJ; Singh H
    Am Fam Physician; 2008 Jun; 77(11):1553-60. PubMed ID: 18581835
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Role of cytochrome P450 enzymes in pharmaceutical preparations].
    Baede van Dijk PA; de Graeff PA; Lekkerkerker JF
    Ned Tijdschr Geneeskd; 1999 Dec; 143(52):2607-11. PubMed ID: 10633805
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of nuclear receptors in pharmacokinetic drug-drug interactions in oncology.
    Harmsen S; Meijerman I; Beijnen JH; Schellens JH
    Cancer Treat Rev; 2007 Jun; 33(4):369-80. PubMed ID: 17451886
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Protein dynamics and imidazole binding in cytochrome P450 enzymes.
    Verras A; Ortiz de Montellano PR
    Biochem Soc Trans; 2006 Dec; 34(Pt 6):1170-2. PubMed ID: 17073778
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.